American Century Companies Inc. Has $15.40 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

American Century Companies Inc. raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 128.5% during the second quarter, HoldingsChannel.com reports. The fund owned 416,000 shares of the biopharmaceutical company’s stock after acquiring an additional 233,928 shares during the quarter. American Century Companies Inc.’s holdings in Celldex Therapeutics were worth $15,396,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CLDX. Victory Capital Management Inc. acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $288,000. Charles Schwab Investment Management Inc. lifted its holdings in Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after purchasing an additional 47,844 shares during the last quarter. UBS Group AG boosted its position in Celldex Therapeutics by 645.9% in the fourth quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock valued at $6,270,000 after buying an additional 136,897 shares in the last quarter. Trexquant Investment LP bought a new stake in Celldex Therapeutics during the fourth quarter worth about $1,246,000. Finally, Aigen Investment Management LP bought a new stake in Celldex Therapeutics during the fourth quarter worth about $251,000.

Celldex Therapeutics Stock Up 0.2 %

Shares of CLDX stock opened at $41.24 on Friday. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -14.47 and a beta of 1.56. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18. The stock has a 50-day moving average price of $38.54 and a 200 day moving average price of $38.74.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on CLDX shares. Wolfe Research assumed coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price on the stock. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price for the company. Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $63.83.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.